English 
Chinese 
Russian 
French Why Your Stem Cells Slow Down After 40 (and What Science Is Doing About It)
Research shows MSC activity drops 40% by age 50. Learn what changes inside aging cells and three emerging therapies showing real results in 2026 clinical trials.
04Sep
28Aug
MSC Clinical Trials: What ISCT Dublin Revealed About Meniscal Repair, Mitochondrial Transfer, and Cell Sourcing
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
27Aug
Stem Cell Therapy for Spinal Cord Injury: What 2026 Research Tells Us About MSC Therapy After SCI
Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.
24Aug
What Happens During Stem Cell Treatment Recovery Week in Bangkok?
Planning a trip to Bangkok for stem cell therapy involves more than just scheduling your procedure date. International patients need to know: What does the post-treatment recovery week actually look like? Whether receiving intravenous (IV) infusions or targeted joint injections, the vast majority of patients experience minimal downtime. Here is a...
22Aug
Stem Cell Therapy for Erectile Dysfunction: A Patient’s Guide to the 2026 Evidence
Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
20Aug
MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
20Aug
MSC-Derived Exosomes for Myocardial Infarction: Delivery Systems, Mechanisms, and the Bench-to-Bedside Pipeline
Eight 2026 studies detail how MSC exosomes inhibit ferroptosis, deliver sustained paracrine signaling via hydrogels, and improve LVEF in rat MI models. Here is what translational researchers need to know before the first Phase 2 exosome trial reads out.
19Aug
Harnessing MSC-Derived Exosomes for Advanced Rheumatoid Arthritis Immunotherapy
Discover the groundbreaking potential of MSC-derived exosomes in revolutionizing Rheumatoid Arthritis immunotherapy. Learn about novel nanoplatforms and their mechanism of action.
18Aug
MSC Therapy for Diabetic Foot Ulcers: 2026 Mechanism, Hydrogel Delivery, and Real-World Trial Outcomes
2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.
17Aug
Allogeneic vs Autologous Stem Cells: What 2026 Evidence Says Is Better
2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.